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Abstract: Aptamers, also known as chemical antibodies, are short single-stranded DNA, RNA or peptide molecules. 
These molecules can fold into complex three-dimensional structures and bind to target molecules with high affinity and 
specificity. The nucleic acid aptamers are selected from combinatorial libraries by an iterative in vitro selection procedure 
known as systematic evolution of ligands by exponential enrichment (SELEX). As a new class of therapeutics and drug 
targeting entities, bivalent and multivalent aptamer-based molecules are emerging as highly attractive alternatives to 
monoclonal antibodies as targeted therapeutics. 
Aptamers have several advantages, offering the possibility of overcoming limitations of antibodies: 1) they can be 
selected against toxic or non-immunogenic targets; 2) aptamers can be chemically modified by using modified nucleotides 
to enhance their stability in biological fluids or via incorporating reporter molecules, radioisotopes and functional groups 
for their detection and immobilization; 3) they have very low immunogenicity; 4) they display high stability at room 
temperature, in extreme pH, or solvent; 5) once selected, they can be chemically synthesized free from cell-culture-
derived contaminants, and they can be manufactured at any time, in large amounts, at relatively low cost and 
reproducibly; 6) they are smaller and thus can diffuse more rapidly into tissues and organs, leading to faster targeting in 
drug delivery; 7) they have lower molecular weight that can lead to faster body clearance, resulting in a low background 
noise for imaging and minimizing the radiation dose to the patient in diagnostic imaging. Thus, the high selectivity and 
sensitivity, ease of screening and production, chemical versatility as well as stability make aptamers a class of highly 
attractive agents for the development of novel therapeutics, targeted drug delivery vehicles and molecular imaging. 
 In the review, we will discuss the latest technological advances in developing aptamers, its application as a novel class of 
drug on its own, as well as in surface functionalization of both polymer nanoparticles or nanoliposomes in the treatment of 
cancer, viral and autoimmune diseases. 
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INTRODUCTION 
 The term ‘aptamer’ was first coined 20 years ago, and is 
derived from the Latin aptus, to fit, and the Greek meros, 
part or region [1]. These small molecules are short stranded 
DNA or RNA molecules that have the ability to fold into 
complex three dimensional structures which bind to target 
molecules with high affinity and specificity [2]. In 1990, the 
laboratories of both Gold and Ellington independently 
pioneered the selection procedures of nucleic acid aptamers 
from combinatorial libraries by an iterative in vitro selection 
procedure known as the ‘systemic evolution of ligands by 
exponential enrichment’ (SELEX) [1, 3].  
 SELEX is the method by which aptamers are selected to 
bind to a particular target from a combinatorial library of 
synthetic oligonucleotides consisting of a pool of single-
stranded DNA fragments with enormous repertoire and 
functionality. The random oligonucleotide library consists of  
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a randomized central region with fixed terminal regions to 
allow primer binding. Typical aptamer sequences are 
between 20 and 60 nucleotides in length, although aptamers 
have been selected at 220 nucleotides long. Randomization 
of the central sequence provides the diversity within the 
library, typically within the range of 1 x 10
15
 independent 
aptamers, which allows for the high probability of a binding 
sequence being presented within the library [1, 3, 4]. 
 Aptamer selection is characterized by the completion of 
successive steps of binding between the random 
oligonucleotide library and a target molecule, separation of 
bound aptamers from unbound sequences, elution of bound 
aptamers from the target and amplification of bound 
aptamers via PCR to form a new, more refined aptamer 
library [4, 5]. Following a number of SELEX cycles (usually 
around 10-15 cycles) that continue to enrich the binding 
species, the library can be cloned and sequenced, followed 
by confirmation of the binding, resulting in an aptamer with 
high specificity and affinity for its target molecule. 
 Due to the evolutionary pressures placed on aptamer 
sequences during the selection process, aptamer sequences 
are optimized primarily towards the binding of ligands. 
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These sequences, which are predominantly unstructured in 
solution, fold upon association with their ligands into 
complex shapes with the ligand becoming an integrated part 
of the nucleic acid structure. It has well been established that 
aptamers bind to their ligands via adaptive recognition 
involving conformational alteration of either the target or the 
aptamer, precise stacking of flat moieties, specific hydrogen 
bonding, and molecular shape complementarity, and these 
multiple, highly specific and spatially distinct contacts across 
the target/aptamer complex are formed without the 
involvement of covalent bonds. While RNA aptamers are 
more susceptible to hydrolysis and present greater problems 
during the selection process, they also provide a much higher 
level of structural diversity than DNA aptamers [6, 7]. One 
of the benefits of aptamers versus their natural counterparts 
is that natural nucleic acids require a biased co-optimization 
of different structural motifs, including ligand binding sites, 
to be part of the intricate network of biological processes. 
Conversely, aptamers generally only have one function, 
which is to bind to their target, thus having a much higher 
affinity for the single target that they have been optimized to 
recognize [6]. Aptamers also share some similarities with 
antibodies, in that they might not be translatable to other 
assays: functioning well in one assay does not necessarily 
mean it will adapt to new applications. They can also bind 
non-specifically to cells, in much the same way that most 
other reagents do. Thus, all cell binding experiments using 
aptamers should include proper negative controls [8].  
 SELEX is, however, a complex process, comprising 
several steps within each cycle, with each step requiring 
optimization for successful SELEX to occur. The most 
critical step of the cycle is the separation of the bound 
species from non-binding species, and given the nature of the 
SELEX cycle, it is not possible to determine success until 
several cycles have been completed, making it a time-
consuming and laborious process. For a laboratory entering 
this area of development, trial and error is necessary to 
optimize buffer conditions, partitioning of bound versus 
unbound species, number of PCR cycles and the total 
number of SELEX cycles to complete the selection. Since 
the first publication in 1990 detailing the selection of the first 
aptamer, numerous methodologies have been described to 
promote efficient partitioning, and increase aptamer affinity 
and specificity [4, 9-15]. 
APTAMERS AS THERAPEUTICS AND THERANO-
STICS 
 Aptamers, as therapeutic molecules, possess numerous 
advantages and disadvantages over other therapeutic entities. 
As small molecules with non-modified nucleic acids, they 
have a half-life of minutes to hours due to nuclease 
degradation and can be cleared rapidly by the kidneys. This 
had led to the use of these unmodified aptamers for the 
treatment of transient conditions, like blood clotting, or for 
the use of treating organs where local delivery is possible, 
such as the eye. It has also led to the suggestion that these 
compounds can be used in vivo diagnostic imaging [16]. 
However, these benefits become disadvantages when 
considering their use as in vivo therapeutic agents, due to 
their inherent instability. It is possible to improve their half-
life through the use of base modifications and the linkage of 
polyethylene glycol (PEG) [17]. Base modifications, 
including 2’-O-methyl pyrimidines, 2’-deoxy purines, and 
2’-fluorine-pyrimidines, have been shown to extend their in 
vivo stability to 86 hours [18]. The first aptamer to be 
approved by the US Food and Drug Administration (FDA) in 
2004, Pegaptanib sodium (Macugen), for the treatment of 
age-related macular degeneration, contains not only 2’-O-
methylated purines, and 2’-fluorine-pyrimidines to protect 
against endonucleases, but also a PEG moiety and a 3’-dT to 
enhance its pharmacokinetic properties and protect it against 
exonuclease attack [19]. These modifications led to Macugen 
having an initial half-life of 1.4h, which was extended to 
131h following all these modifications [20]. In this way, it is 
possible to tailor the various chemical modifications to 
achieve a desired pharmacokinetic and biodistribution profile 
of a specific aptamer for a specific clinical application. 
These are the properties that make aptamers such promising 
therapeutic agents.  
 While aptamers can be selected against virtually any 
target, their mode of action is dependent on their target. In 
most cases, the actual binding of the aptamer to the target 
inhibits its biological activity, with this being due to 
interference with the enzymatic catalytic site, or ligand 
receptor recognition sites, or possibly inducing allosteric 
effects, such as conformational changes resulting in loss of 
function, or through interaction with its natural ligand [17, 
18]. Due to loss of function, aptamers have found a niche in 
virtually every area of pathology, including vaccine 
production [21, 22], virology [23], parasitology [24, 25], and 
oncology [26, 27]. 
IMMUNOMODULATION 
 Virology is one area that can be greatly benefited from 
aptamer research. Vaccination and immunomodulation has 
proven immensely beneficial to human health, as evidenced 
by the great success of the smallpox, measles, polio and 
rabies vaccines, though there are several inherent problems 
associated with vaccine production, including both the 
genetic instability and heat sensitivity of the vaccines [28]. 
Aptamers can at least overcome the heat sensitivity, being 
highly stable at room temperature, and given the ease of 
selection and production, these nucleic acids can be quickly 
selected against new emerging strains [20, 29]. Nucleic acids 
can elicit a broad spectrum activity against a wide range of 
viruses, or be designed against a specific viral strain. These 
aptamer based drugs can stimulate the host’s immune 
response and offer protection against viruses regardless of 
origin or genetic mutations. Indeed, studies have already 
been successfully completed using aptamers that inhibit viral 
enzymes, including proteolytic processing, reverse 
transcription and chromosomal integration, as well as viral 
expression, packaging and entry. Several aptamers have been 
shown to interact with viral coats that cause pandemic 
zoonotic viral respiratory infections [21, 22].  
 HIV has become a popular target for aptamer research, 
with one aptamer entering clinical development which 
inhibits HIV replication [23]. HIV binds to the CD4 receptor 
on T cells to enter the cell through the use of its gp120 
envelope glycoprotein. The extensive glycosylation of gp120 
allows HIV to evade the immune response. However, the 
small size of aptamers allows them to bind to the small 
conserved domains of gp120, whereas large molecules, such 
120    The Open Conference Proceedings Journal, 2010, Volume 1 Shigdar et al. 
as antibodies, can’t. In vitro studies have shown that these 
aptamers were capable of blocking cellular infection with 
HIV by blocking the interaction between HIV and its 
receptor [26]. Hepatitis C has also received attention, with 
two aptamers having been developed against it, achieving a 
70% inhibition of the maltose-binding protein-NS3 (MBP-
NS3) protease activity [2].  
 As well as targeting viruses, aptamers can also be 
selected against bacteria, thus acting as antibiotics if selected 
to inhibit a crucial bacterial protein or to disrupt cell 
membrane formation. In addition, by linking the aptamer to 
an antibiotic agent, these molecules could be used as a 
‘targeting system’ directed against specific pathogens [9]. 
PARASITOLOGY 
 One of the most promising areas of aptamer research is in 
the treatment of endemic diseases in developing countries. 
These diseases are in need of novel, effective and rapid 
treatments. Parasitic infections, the causative agent of the 
majority tropical diseases, have proven interesting targets. 
Human African trypanosomiasis, caused by a protozoan 
parasite of the genus Trypanosoma, is known to cause 
sleeping sickness and Chagas’ disease. Again, in vitro 
studies have proven therapeutic value in the RNA aptamers 
that have been selected against the trypanosome cell surface 
[24, 25]. Trypanosoma cruzi is the causative agent of 
Chagas’ disease. RNA aptamers have been developed which 
bind to the parasite receptors for host-cell matrix molecules 
on the trypomastigote cell surface. The biological activity in 
vitro blocked cell invasion by 50-70%, though the results 
also indicate that there are other mechanisms by which T. 
cruzi invades the cell [18].  
 Another parasite that has been the focus of aptamer 
research is the Plasmodium parasite, the causative agent of 
malaria. This disease is a devastating and frequently fatal 
disease. Molecular tools for gene disruption have been 
developed which has led to the identification of several 
parasite-derived proteins. Aptamers have been developed 
against these proteins of P. falciparum and have been 
postulated to be promising candidates as adjunct therapy in 
severe malaria [18, 30]. 
PRIONS 
 Prion diseases have also been benefited from this area of 
research, with aptamers raised against the insoluble amyloid 
conformer of the prion protein in transmissible spongiform 
encephalopathies, such as bovine spongiform 
encephalopathy and Creutzfeldt-Jakob disease. Aptamers 
have been developed against the abnormal prion protein and 
can distinguish between the abnormal and its normal 
counterpart even though they differ only in secondary and 
tertiary structure. Cell based assays have shown that these 
aptamers can prevent the accumulation of the insoluble 
abnormal form or the prion protein [9, 22, 31].  
COAGULATION 
 The pathological formation of a clot in response to 
injury, stasis, or hypercoagulability follows abnormal 
coagulation. Aptamers with moderate affinity have been 
developed against thrombin to prolong the clotting time of 
human plasma. A DNA aptamer with a half-life of 
approximately 1-2 min was developed against thrombin for 
use in surgical indications requiring regional anticoagulation 
of an extracorporeal circuit. There are a number of factors 
and cofactors involved in the clotting cascade, with the 
enzymatic cascade initiated by the protease FVIIa with the 
aid of its cofactor, tissue factor. An RNA aptamer with 2-
fluoropyrimidines has been generated against FVIIa, with a 
half-life of about 15h, and has been shown to inhibit the 
factor X activation by 95% by preventing formation of an 
active FVIIa-tissue factor complex [32]. The aptamer 
targeting factor IXa (RB006) has now entered phase 2b 
clinical trials, aimed at enrolling 800 patients with acute 
coronary syndrome undergoing cardiac catheterization. This 
aptamer has had an ‘antidote’ designed against it which has 
shown a 51 ± 14% to 68 ± 15% successful partial reversal of 
RB006 activity, and a 93 ± 11% to 103 ± 13% complete 
reversal of RB006 activity in phase 2a clinical trials [33]. 
INFLAMMATORY DISORDERS 
 Inflammatory bowel disease (IBD) is another area of 
medicine benefiting from the area of aptamer development. 
Mucosal biopsies in patients suffering from IBD are 
characterized by an increased expression of the inducible 
form of nitric oxide synthase (iNOS) and increased levels of 
the radical nitric oxide. Inhibition of iNOS expression with 
aptamers has been proven in animal studies in areas of 
encephalomyelitis, sepsis, cerebral and renal ischemia, 
showing a potential therapeutic application in the treatment 
of IBD [34].  
 Autoimmune diseases occur when the patient develops 
antibodies against their own cells or tissues. One example is 
Myasthenia gravis, a neuromuscular disorder characterized 
by muscular weakness and fatigue resulting from an 
antibody-mediated autoimmune response to the nicotinic 
acetycholine receptor (AChR). Animal models have shown 
that a modified RNA aptamer against these autoantibodies 
can inhibit the autoimmune response [9, 26].  
CANCER 
 The development of novel approaches for early cancer 
detection and effective therapy will significantly contribute 
to the improvement of patient survival [35]. Cancer is a 
disease that affects all age groups and places an extreme 
burden on patients, families and societies and it’s the leading 
cause of death in the Western industrialized world [36, 37]. 
It is pointless to select an aptamer against any target, and for 
an aptamer to have an effect, it must be directed against a 
target of importance [32]. The four basic targeting criteria of 
monoclonal antibodies for cancer therapeutic applications 
are that the antigen of interest is overexpressed by tumor 
cells, the antigen participates as a principle component in the 
progression of the disease, the antigen is stable in its present 
form on the tumor cell surface, and that the antigen is 
expressed by a large percentage of tumor cells and a large 
variety of tumors, and these same criteria can be applied to 
aptamer research [38]. Cancerous cells have numerous 
biologically important targets and the majority of these are 
already being targeted by immunotherapy. Conventional 
cancer treatment includes surgery, radiotherapy and 
chemotherapy. However, the small therapeutic window of 
killing cancerous cells while preserving normal cells is a 
major limitation. Tumor–specific monoclonal antibodies 
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allow for the specific targeting of tumors, thus reducing the 
maximum tolerated dose and minimizing side effects, with 
current technology focusing on antibodies and antibody 
fragments against almost any tumor antigen [36, 37]. This 
technology isn’t new, and aptamers have again found their 
niche in this area of research, having many advantages over 
antibodies, including low immunogenicity and a much 
smaller size, allowing for rapid diffusion [37]. The most 
advanced aptamer, in terms of clinical trials, in the field of 
cancer is AS-1411, which appears to bind to cell surface 
nucleolin and internalizes, leading to an inhibition of DNA 
replication. This has led to multiple cases of stable disease 
and one near complete response in a patient with renal 
cancer. In addition these promising signs were observed with 
no significant adverse effects [16, 17]. Aptamers that are 
currently in pre-clinical stages include a chemosensitizer for 
the treatment of cancer and retinopathy (ARC-127), an 
inhibitor of the isoform b of transcription factor HMGA1 
(NOX-A50), and the anti-MUC1 aptamer designed against 
the Muc-1 protein in epithelial malignant cells [17]. 
 Aptamers have also been selected against cytotoxic T-
cell antigen-4 (CTLA-4), with inhibition thought to enhance 
anti-tumor immunity. This inhibition of CTLA-4 by 
aptamers induces the antigen-dependent expansion of T cells 
by blocking inhibitory signals delivered by CTLA-4. The 
efficacy of CTLA-4 aptamer in tumor suppression has been 
demonstrated in murine cancer models in which several 
aptamers have been shown to have similar, or superior 
functionality, to the anti-CTLA-4 antibody [26, 27].  
APTAMER CONJUGATION 
 One of the benefits of targeted cancer treatments with 
antibodies or aptamers is the ability to directly couple 
therapeutic agents or package these therapeutic agents into 
particles that can then be delivered to specific cells [7]. Gene 
silencing siRNAs have been linked to aptamers to 
specifically deliver siRNAs to target cells, thus removing 
one of the limitations of using siRNA. This has been 
successfully demonstrated with a prostate specific membrane 
antigen (PSMA) aptamer delivering siRNA against pro-
survival genes [16, 39, 40]. PSMA has also been directly 
conjugated to a chemotherapeutic drug, doxorubicin. 
Doxorubicin can directly intercalate into DNA, preferentially 
binding to double stranded 5’-GC-3’ or 5’-CG-3’ sequences. 
The cytotoxicity of the aptamer-doxorubicin conjugate was 
significantly enhanced against PSMA-positive cells as 
compared to PSMA-negative cells [41].  
 In addition to the anthracycline drug, doxorubicin, other 
drugs can be conjugated to aptamers through solid-phase 
synthesis or post-synthesis by incorporating an amino or 
thiol group at one end of the oligonucleotide during their 
assembly. Doxorubicin has also been attached by the 
addition of an acid-labile hydrazone linker to a 41-nucleotide 
long tyrosine kinase 7 PTK-7-specific DNA aptamer which 
then selectively internalizes into CCFR-CEM cells (T-cell 
acute lymphoblastic leukemia cells) with no apparent 
reduction in aptamer affinity for its target, and no non-
specific internalization of the drug [7].  
 As well as conjugating drugs to the aptamer, 
radionuclides can be attached, allowing for both imaging and 
killing cancerous cells. Tenascin-C is a large hexameric 
glycoprotein associated with the extracellular matrix and 
expressed during tissue remodeling events occurring during 
angiogenesis and tumor growth. The aptamer directed 
against it, TTA1 has had a metal chelator, mercaptol-acetyl 
diglycine, incorporated into the 5’ end which allows it to 
chelate Technetium-99m and has been used to successfully 
determine its biodistribution in vivo in a human glioblastoma 
nude mouse model [7]. Tenascin-C is not only a marker of 
glioblastomas, however, and this radionuclide conjugate has 
been shown to be taken up by a variety of solid tumors, 
including breast, lung and colon. Tumor uptake was rapid 
and blood, kidney and non-target tissue clearance was fast, 
providing a clear tumor imaging modality [16]. 
 Aptamers are the ideal small molecule for conjugation to 
nanoparticles. Larger molecules, such as antibodies or 
proteins, together with their conjugated nanoparticles, can 
get ‘caught up’ by the reticular endothelial system and/or 
mononuclear phagocyte system. In contrast aptamer-
nanoparticle conjugates are able to travel through the 
microvasculature as well as the tumor interstitium, a function 
that depends strongly and inversely on size [42]. Aptamers 
show superiority over other targeting ligands due to their 
smaller size which allows for a superior tissue penetration. 
Nanoparticle systems offer major improvements in 
therapeutics with aptamers having been designed to deliver 
toxins, radioisotopes and chemotherapeutic agents 
encapsulated in nanoparticles [7, 38]. Nanoparticles that are 
currently in use for cancer therapeutic applications include 
carbon nanotubes, micelles, dendrimers, liposomes, and 
metallic/polymeric/protein/ceramic/viral nanoparticles, with 
the material properties of each nanoparticle system having 
been specifically developed to enhance their delivery to 
tumors. Surface functionalization with the use of PEG can 
reduced the opsonization effects from the adherence of 
serum proteins, thus increasing circulation times. Current US 
FDA and European Medicines Agency approved 
nanoparticles, however consist of liposomes and PEGylated 
liposmes, and recently albumin-bound nanoparticles, 
containing either doxorubicin, daunorubicin or paclitaxel 
[38]. However, liposome formulations are the most 
successful drug delivery system. Liposome-aptamer 
conjugates have been shown to have increased circulation 
times and the aptamers have aided the delivery of the 
conjugate to their desired site of action [7]. One of the main 
problems associated with the use of chemotherapeutic drugs, 
especially anthracyclines such as doxorubicin, is 
cardiotoxicity. Through the use of targeted drug delivery 
such as intercalating it directly into the aptamer, or placing it 
within the liposome, avoid damage to healthy tissue, thus 
reducing the cardiotoxicity effects [39]. 
 Of the four most common cancer types in the US (breast, 
lung, colorectal and prostate cancer), only breast (MUC-1) 
and prostate cancer (PSMA) have so far had aptamers 
successfully designed against a suitable target [7, 38]. One 
group has attached their PSMA aptamer to a functionalized 
nanoparticle containing docetaxel and showed negligible 
cytotoxicity and complete tumor regression in 70% of their 
study animals. In a similar study by the same group, more 
than four times greater accumulation was observed in 
subcutaneously injected human prostate cancer xenografts in 
rats with aptamer-targeted nanoparticles versus non-targeted 
nanoparticles [7, 43]. 
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MULTIVALENT APTAMERS 
 One of the main problems associated with drug targeting 
is that the terminology would seem to imply a ‘smart 
missile’ type of activity. These drug carriers do not actively 
seek out target cells, but rather stumble on to their targets. In 
this way, the aptamer-drug conjugate must combine both 
‘passive’ and ‘active’ targeting. Firstly, the conjugate must 
be able to pass through the fenestraes on the tumor blood 
vessels by chance through convectional flow and random 
diffusional processes. This passive targeting must, however, 
overcome the increased hydrostatic forces associated with 
the tumor extracellular space. Once the conjugate has 
successfully evaded these mechanisms, it must still be viable 
enough to attach to its specific target. If the drug is released 
prematurely, there may be insufficient accumulation at the 
tumor site [44]. These problems have been overcome due to 
the various modifications and conjugation to liposomes. 
However, once the drugs reach the tumor and retards growth, 
it has been postulated that the rapid blood flow, once very 
attractive initially to promote tumor targeting, will decrease 
due to a decreasing size and a normal supply of blood flow 
being sufficient to maintain its size. In addition, tumor cells 
are very heterogeneous and the remaining cancer cells may 
not possess the correct marker on its surface [44]. One 
method to overcome this very positive size reduction is to 
conjugate aptamers against different target. Previous work 
has formed multivalent aptamers against B52 in Drosophila 
and the cytotoxic T-cell antigen-4 (CTLA-4). The 
multivalent antagonist aptamer directed against B52 
demonstrated increased avidity and potency. The CTLA-4 
was postulated to promote T-cell activation and generate an 
anti-tumor immune response through inhibition. Through the 
formation of a tetrameric CTLA-4 aptamer, the immune 
response was enhanced both in cell culture and in vivo [7, 
39].  
 Tumor targeting is not the only condition benefiting from 
multivalent aptamers. A bivalent aptamer consisting of two 
separate RNA aptamers binding two distinct stem-loop 
structures within the 5’-UTR of HIV has shown a more 
stable interaction with the target sequences in vitro compared 
to the individual aptamers. Bivalent aptamers targeting 
thrombin have also shown increased avidity and, therefore, 
enhanced anticoagulation effects [39].  
CELL SELEX 
 While multivalent aptamers can solve some of the issues 
surrounding heterogeneity and increase avidity and potency, 
a relatively new method of selecting aptamers is gaining 
increased interest. So far, the aptamers mentioned have been 
developed against known targets. Through the use of whole 
cells, aptamers can be designed against targets on the cell 
surface without prior knowledge of the known target. In this 
way, it is possible to develop aptamers against specific cell 
types, such as cancer cells, that don’t bind to normal cells. 
This method has successfully been used to recognize human 
receptor tyrosine kinase (RET) [45], whereas Tan used this 
method to design aptamers against the cultured precursor T 
cell acute lymphoblastic leukemia cell line (CCRF-CEM) 
[46]. In addition, this method can also be used to 
differentiate between different cancer cell types or 
biomarkers differentially expressed under varying 
physiological conditions. It also makes it possible to select 
aptamers against proteins with cancer-derived post-
translational modifications. A benefit of using SELEX is that 
a pool of aptamers is selected following the SELEX cycle. 
Therefore, it is highly probable that following cell-SELEX, 
several aptamers directed against different cell surface 
targets are produced. This can be greatly beneficial when 
targeting a disorder, such as cancer, that has a heterogeneous 
composition [18, 46, 47].  
Table 1. Summary of Therapeutically-Targeted Aptamers  
TAR decoy/Tat aptamers 
HIV-1 Rev response element 
HIV reverse transcriptase 
HIV gp120 
Hepatisis C virus NS3 
Trypanosoma cruzi 
Anti-Viral 
PrPSc 
Thrombin 
Factor VIIa 
Factor IXa 
Anti-coagulation 
Activated protein C 
Vascular endothelial growth factor (VEGF) 
Angiopoietin-2 
Anti-angiogenesis 
Angiogenin 
Human neutrophil elastase 
Platelet-derived growth factor 
P-Selectin/ L-Selectin/ Sialyl Lewis X 
Human non-pancreatic secretory phospholipase 
A2 
Nuclear factor -B (NF- -B) 
Anti-
inflammatory 
Human complement C5 
Transcription factor E2F 
Prostate specific membrane antigen 
VEGF 
Anti-proliferation 
Tenacin-C 
Insulin receptor 
Acetylcholine receptors 
Immunoglobulin E 
Human interferon- 
Cytotoxic T cell antigen-4 
Immune 
modulation 
CD4 
MUC-1 
EGFR-3 
Nucleolin 
Pigpen 
Cancer targeting 
ERK2 
 
CONCLUSIONS 
 While Macugen is the only FDA approved aptamer 
currently on the market, Aptanomics (Lyon, France) are 
working on therapeutic targets involved in signaling 
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pathways that are deregulated in a broad range of cancers, 
including a Bcl antagonist and a unique kinase antagonist, 
whereas Archemix (Cambridge, MA, USA) have 9 
therapeutic aptamers currently in either phase I or phase II 
clinical trials spanning hematology, cardiovascular disease, 
oncology and age-related macular degeneration. While the 
therapeutic aptamers reviewed here are nowhere near a 
complete list of all the aptamers currently being investigated 
as therapeutic molecules (see Table 1 [2, 48, 49] for 
additional aptamer therapeutics), it does provide an overview 
and provides a basis for further reading into this interesting 
area of therapeutic medicine. There are many more potential 
areas of research that can be explored further, and hopefully 
soon, some of the more promising candidates will be 
approved by the US FDA for treatment of these 
diseases/disorders. 
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AChR  = Acetylcholine receptor 
CTLA-4 = Cytotoxic T-cell antigen-4 
FDA = Food and Drug Administration 
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MBP-NS3 = Maltose-binding protein-NS3 
PEG = polyethylene glycol 
PSMA = prostate specific membrane antigen 
SELEX = Systemic evolution of ligands by 
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